Jeff Smith

3.3k citations

52 papers · 2.4k indexed · 3 hit papers · h-index 25

Impact in

Psychiatry and Mental health top 1%
- Migraine and Headache Studies
- Psychosomatic Disorders and Their Treatments
Gastroenterology top 2%
- Gastroesophageal reflux and treatments

Papers in ⓘ

Psychiatry and Mental health 17
- Migraine and Headache Studies 17
- Psychosomatic Disorders and Their Treatments 3
Surgery 12
- Helicobacter pylori-related gastroenterology studies 8

Co-authors: Joe Hirman (14 shared papers)Roger Cady (11 shared papers)David M. Biondi (8 shared papers)Barbara Schaeffler (10 shared papers)Susan Pederson (6 shared papers)R E Pounder (6 shared papers)Richard B. Lipton (7 shared papers)Brent Allan (4 shared papers)
Journals: Neurology (9 papers)Alimentary Pharmacology & Therapeutics (6 papers)Journal of Clinical Oncology (4 papers)Gut (3 papers)Cephalalgia (2 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Jeff Smith

50 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Efficacy and safety of eptinezumab in patients with chronic migraine 2020 · 273 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Neurology
2020 Cephalalgia
2014 The Lancet Neurology

Peers

Countries citing papers authored by Jeff Smith

Since Specialization

Citations

This map shows the geographic impact of Jeff Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Smith more than expected).

Fields of papers citing papers by Jeff Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Smith. The network helps show where Jeff Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside Jeff Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeff Smith Line = papers co-authored together Jeff Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial The Lancet Neurology ·David W. Dodick, Peter J. Goadsby, Stephen D. Silberstein, Richard B. Lipton, Jes Olesen, Messoud Ashina, Kerri Wilks, David Kudrow, Robin Kroll, Bruce Kohrman, Robert R. Bargar, Joe Hirman, Jeff Smith Hit paper breakdown →	2014	299
2	Efficacy and safety of eptinezumab in patients with chronic migraine Neurology ·Richard B. Lipton, Peter J. Goadsby, Jeff Smith, Barbara Schaeffler, David M. Biondi, Joe Hirman, Susan Pederson, Brent Allan, Roger Cady Hit paper breakdown →	2020	273
3	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) Cephalalgia ·Messoud Ashina, Joel R. Saper, Roger Cady, Barbara Schaeffler, David M. Biondi, Joe Hirman, Susan Pederson, Brent Allan, Jeff Smith Hit paper breakdown →	2020	264
4	A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer Expert Opinion on Biological Therapy ·Trevor J. Bayliss, Jeff Smith, Michael Schuster, Konstantin H. Dragnev, James R. Rigas	2011	203
5	Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine Alimentary Pharmacology & Therapeutics ·Chuka Nwokolo, Jeff Smith, C. J. Gavey, A. M. Sawyerr, R E Pounder	1990	125
6	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial Cephalalgia ·David W. Dodick, Richard B. Lipton, Stephen D. Silberstein, Peter J. Goadsby, David M. Biondi, Joe Hirman, Roger Cady, Jeff Smith	2019	113
7	Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer's disease Experimental Neurology ·Marilyn J. Duncan, Jeff Smith, Kathleen M. Franklin, Tina L. Beckett, M. Paul Murphy, Daret K. St. Clair, Kevin D. Donohue, Martin Striz, Bruce F. O’Hara	2012	87
8	A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate Annals of the Rheumatic Diseases ·Philip J. Mease, Vibeke Strand, Levan Shalamberidze, Aleksandar Dimić, Т. А. Раскина, Lian Xu, Y Liu, Jeff Smith	2012	74
9	Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study The Journal of Headache and Pain ·Stephen D. Silberstein, Merle L. Diamond, Nada Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith	2020	72
10	Thromboprophylaxis in medically ill patients at risk for venous thromboembolism American Journal of Health-System Pharmacy ·E Burleigh, Cheng Wang, David A. Foster, Sivana Heller, Dennis J. Dunn, Kaveh Safavi, Brian P. Griffin, Jeff Smith	2006	65
11	Eradication of Helicobacter pylori abolishes 24‐hour hypergastrinaemia: a prospective study in healthy subjects Alimentary Pharmacology & Therapeutics ·Emily Prewett, Jeff Smith, Chuka Nwokolo, Mark Hudson, A. M. Sawyerr, R E Pounder	1991	62
12	Restricting feeding to the active phase in middle-aged mice attenuates adverse metabolic effects of a high-fat diet Physiology & Behavior ·Marilyn J. Duncan, Jeff Smith, Julio Narbaiza, F. Mueez, L.B. Bustle, Saqib Qureshi, Charles Fieseler, Sandra J. Legan	2016	58
13	The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate Alimentary Pharmacology & Therapeutics ·Chuka Nwokolo, C. J. Gavey, Jeff Smith, R E Pounder	1989	57
14	Influence of aging on Bmal1 and Per2 expression in extra-SCN oscillators in hamster brain Brain Research ·Marilyn J. Duncan, Jeffrey R. Prochot, Daniel H. Cook, Jeff Smith, Kathleen M. Franklin	2012	54
15	Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut ·CU Nwokolo, Jeff Smith, A. M. Sawyerr, R E Pounder	1991	52
16	Drug-Induced Changes of Plasma Gastrin Concentration Gastroenterology Clinics of North America ·R E Pounder, Jeff Smith	1990	49
17	Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine Pharmacology Research & Perspectives ·Brian Baker, Barbara Schaeffler, Martin Béliveau, Igor Rubets, Susan Pederson, MyMy Trinh, Jeff Smith, John Latham	2020	48
18	Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study Clinical Therapeutics ·Timothy R. Smith, Marina Janelidze, George Chakhava, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Jeff Smith, Barbara Schaeffler	2020	41
19	Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing Headache The Journal of Head and Face Pain ·David W. Dodick, Christopher Gottschalk, Roger Cady, Joe Hirman, Jeff Smith, Steve Snapinn	2020	38
20	Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. Journal of Clinical Oncology ·James R. Rigas, M. Schuster, С. В. Орлов, Branislav Milovanović, K. Prabhash, Jeff Smith, (unknown)	2010	36

About Jeff Smith

Jeff Smith is a scholar working on Psychiatry and Mental health, Surgery, Physiology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 52 papers that have together received 2.4k indexed citations. Recurring topics across this work include Migraine and Headache Studies (17 papers), Helicobacter pylori-related gastroenterology studies (8 papers), Trigeminal Neuralgia and Treatments (6 papers), Gastroesophageal reflux and treatments (6 papers), Circadian rhythm and melatonin (5 papers), Sympathectomy and Hyperhidrosis Treatments (4 papers), Psychosomatic Disorders and Their Treatments (3 papers) and Cytokine Signaling Pathways and Interactions (2 papers). The work is most often cited by research in Psychiatry and Mental health (1.2k citations), Gastroenterology (277 citations), Pathology and Forensic Medicine (873 citations), Endocrine and Autonomic Systems (221 citations) and Physiology (758 citations). Jeff Smith has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Joe Hirman, Roger Cady, David M. Biondi, Barbara Schaeffler, Susan Pederson, R E Pounder, Richard B. Lipton, Brent Allan, Peter J. Goadsby and A. M. Sawyerr. Their work appears in journals such as Neurology, Alimentary Pharmacology & Therapeutics, Journal of Clinical Oncology, Gut and Cephalalgia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact